Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial

IMPORTANCE: Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. OB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Salazar, Lupe G., Lu, Hailing, Reichow, Jessica L., Childs, Jennifer S., Coveler, Andrew L., Higgins, Doreen M., Waisman, James, Allison, Kimberly H., Dang, Yushe, Disis, Mary L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824239/
https://ncbi.nlm.nih.gov/pubmed/28114604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.6007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados